OBR Daily Commentary

forumImage

Value-Based Oncology Care an Imperfect Proposition Still

(Medscape Medical News) Apr 7, 2017 - ASCO said its value framework is still not ready for use, while a cancer center shared how it has implemented the Oncology Care Model, but has no data yet.

Read Article arrow

William McGivney, PhD (Posted: April 12, 2017)

quotesThe developers of Value Metric Frameworks continue to struggle to make them relevant and also to make them usable and utilized by a meaningful number of policy-makers and clinicians. In the MedScape article, the key point was made with surprising honesty by ASCO’s Dr. Grubbs who was quoted regarding the ASCO Value Score Framework: “The organization is working to include cross-trial comparisons”, said Dr Grubbs. "Until we have that, there's going to be limited benefit to this.” This was an obvious observation made by many when the ASCO Value Score Model was first introduced. Mandating the use of head to head comparator trials as the source of data and other limiting characteristics created a model that once again ended up as confirmation of the saying, “The Perfect is the Enemy of the Good”. In what I called “The Rush to Value” in my analysis for a journal in July of 2015, organizations and individuals raced to the spotlight for presumptive crowning as “Value Czars” with incompletely thought-out products. Here we are two years later and these products languish. Actually, the one product that still has “legs” is the ICER analytical model. However, any momentum that ICER had was substantially diminished by the results of the 2016 Presidential election. The pronouncement that many oncologists do not know the price of the drugs that they prescribe continues to amaze me. I submit that this population of docs will not be interested in understanding and reviewing results of the many “Value” Models out there. For the others, a simple statement of Price will probably facilitate the prescriber’s understanding of the Value of what she/he is prescribing. quotes

Reply

Add Comment 1 Comment(s)

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...